1-13 of 13
brentuximab vedotin
Close
Sort by
Journal Articles

Novel agents and immune invasion in Hodgkin lymphoma

Reid W. Merryman, Ann LaCasce
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 243–248.
https://doi.org/10.1182/hematology.2019000029
Published: 2019
Journal Articles

Emerging strategies in peripheral T-cell lymphoma

Neha Mehta-Shah
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 41–46.
https://doi.org/10.1182/hematology.2019000012
Published: 2019
Journal Articles

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Scott F. Huntington
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 252–259.
https://doi.org/10.1182/hematology.2019000030
Published: 2019
Journal Articles

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Pamela Blair Allen, Ann S. LaCasce
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 249–251.
https://doi.org/10.1182/hematology.2019000077
Published: 2019
Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.
https://doi.org/10.1182/hematology.2019000028
Published: 2019
Journal Articles

Where does PD-1 blockade fit in HL therapy?

Alex F. Herrera
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 213–220.
https://doi.org/10.1182/asheducation-2018.1.213
Published: 2018
Journal Articles

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Michael A. Spinner, Ranjana H. Advani
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 200–206.
https://doi.org/10.1182/asheducation-2018.1.200
Published: 2018
Journal Articles

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

Alison J. Moskowitz
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 207–212.
https://doi.org/10.1182/asheducation-2018.1.207
Published: 2018
Journal Articles

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Nancy L. Bartlett
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 317–323.
https://doi.org/10.1182/asheducation-2017.1.317
Published: 2017
Journal Articles

Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Craig Moskowitz
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 331–338.
https://doi.org/10.1182/asheducation-2016.1.331
Published: 2016
Journal Articles

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era

Solomon A. Graf, Ajay K. Gopal
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 151–157.
https://doi.org/10.1182/asheducation-2014.1.151
Published: 2014
Journal Articles

Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer

Jonathan G. Drachman, Peter D. Senter
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 306–310.
https://doi.org/10.1182/asheducation-2013.1.306
Published: 2013
Journal Articles

Novel therapy for Hodgkin lymphoma

Connie Lee Batlevi, Anas Younes
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 394–399.
https://doi.org/10.1182/asheducation-2013.1.394
Published: 2013